Skip to main content
Abliva logo

Abliva — Investor Relations & Filings

Ticker · ABLI ISIN · SE0002575340 LEI · 5493005YV22OTMUHZ183 ST Manufacturing
Open in API
Filings indexed 594 across all filing types
Latest filing 2022-06-08 Report Publication Anno…
Country SE Sweden
Listing ST ABLI

About Abliva

https://abliva.com

Abliva is a biopharmaceutical company that discovers and develops medicines for the treatment of primary mitochondrial diseases. These are rare, congenital, and often severe genetic disorders that occur when the cell's energy converters, the mitochondria, are dysfunctional. The company's research and development is focused on creating novel therapies aimed at restoring mitochondrial function and addressing the significant unmet medical needs of patients. Abliva's primary goal is to deliver treatments that provide meaningful clinical benefits for individuals suffering from these debilitating conditions.

Recent filings

Filing Released Lang Actions
Abliva publishes prospectus in connection with fully underwritten rights issue and admission to trading of newly issued shares
Report Publication Announcement Classification · 1% confidence The document is a press release dated June 8, 2022, announcing that Abliva has published a prospectus related to a fully underwritten rights issue and the admission to trading of newly issued shares. The key action described is the publication of the prospectus, which contains details about the rights issue (subscription price, dates, underwriting). Since the document itself is an announcement about the availability and approval of a formal document (the prospectus) and details the mechanics of a financing event (rights issue), it strongly aligns with the 'Capital/Financing Update' (CAP) category. While it announces a prospectus, the core subject matter is the capital raise itself, making CAP more specific than RPA or RNS. The document is relatively short and focuses on the financing terms and the publication of the prospectus.
2022-06-08 English
Abliva offentliggör prospekt med anledning av fullt garanterad företrädesemission och upptagande till handel av nyemitterade aktier
Capital/Financing Update Classification · 1% confidence The document is a press release dated June 8, 2022, announcing that the Board of Directors has approved and registered a prospectus ('Prospektet') with the Swedish Financial Supervisory Authority (Finansinspektionen). This prospectus relates to a rights issue (företrädesemission) and the admission to trading of newly issued shares following a directed issue and conversion of convertible debt. The text explicitly mentions the details of the rights issue (subscription price, dates, guaranteed amount) and directs the reader to the full prospectus available on the company's and banks' websites. Since the document itself is an announcement about the publication of a prospectus related to a capital raising/share issue, it fits the description of a Capital/Financing Update (CAP) or potentially a Report Publication Announcement (RPA) if the focus was solely on the publication event. However, the core subject matter is the financing activity (rights issue and share admission) which is strongly covered by 'CAP'. Given the detailed financial terms provided (price, dates, amount raised), CAP is a better fit than the general RPA, although it is an announcement *of* the prospectus. Since the document details the terms of the financing, I classify it as CAP.
2022-06-08 Swedish
Abliva beslutar om en kapitalanskaffning om 200 MSEK för att finansiera fas 2/3-studie med KL1333 till interimsanalys och tar in nya globala life science-specialistinvesterare och institutionella inve
Capital/Financing Update Classification · 1% confidence The document is a press release announcing a significant corporate financing event: a directed share issue (Riktade Emissionen) and a rights issue (Företrädesemissionen) totaling approximately 200 MSEK. It details the terms, use of proceeds (funding clinical trials), participation of new and existing investors, and guarantees. This content directly relates to fundraising, capital structure changes, and financing activities. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). Although it mentions a conference call, the primary focus is the capital raise itself, not just the transcript (CT) or a general regulatory announcement (RNS).
2022-06-01 Swedish
Abliva decides on a SEK 200 million financing to fund Phase 2/3 study of KL1333 to interim analysis and bring in new global life science and institutional investors
Share Issue/Capital Change Classification · 1% confidence The document is a press release dated June 1, 2022, announcing a significant financing event for Abliva AB, involving a directed issue of SEK 150 million and a rights issue of SEK 50 million, totaling SEK 200 million. This clearly falls under the category of updates on company fundraising and capital structure changes. The specific definition matching this content is 'Capital/Financing Update' (Code: CAP). Although it mentions a conference call, the primary focus and bulk of the text detail the financing terms, use of proceeds, and shareholder dilution, making CAP the most accurate classification over CT or RPA.
2022-06-01 English
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Delårsrapport januari – mars 2022' (Interim Report January – March 2022) and contains comprehensive financial data, including income statements, key performance indicators, and detailed management commentary on business operations, clinical trials (KL1333, NV354), and strategic outlook. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q1 2022
2022-05-31 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Interim Report January – March 2022' and contains specific financial data (Net revenues, Loss before tax, Loss per share) for the first quarter of 2022. It provides a comprehensive overview of company activities, financial performance, and strategic outlook for the period. It meets the criteria for an Interim/Quarterly Report (IR) as it contains substantive financial statements and analysis for a period shorter than a full fiscal year. Q1 2022
2022-05-31 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.